The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index, and 1 are not checked yet.
Adverse effects of heavy cannabis use: even plants can harm the brain
Open accessAbstract
1. Introduction The spread of laws legalising cannabis for medicinal or recreational use has been accompanied by more relaxed attitudes towards cannabis. Data from the United States show that in states that have legalised cannabis, prevalence of daily, weekly, and monthly cannabis use was 11.3%, 18.3%, and 25.0% respectively, whereas in countries where it is still illegal, it was lower (7.4%, 11.6%, and 16.8% respectively).46 Evidence indicates a trend of increase among adolescents,58 a particular vulnerable category for the initiation of substance use.114 In parallel, we have seen the concentration of THC (Δ-9-tetrahydrocannabinol) in the cannabis sold both in the United States and in Europe rising and those types of cannabis with high THC,35 and a corresponding decrease of cannabidiol (CBD) content,17,35,95 becoming more widely available. Most commonly, cannabis is used for its enjoyable effects, the “high” feeling.69 In addition, in those countries where its use has been legalised, many people smoke cannabis for medical use, anxiety, depression, and pain relief,71 with those suffering from chronic pain being at higher risk of developing cannabis use disorder (CUD).57 This review aims to challenge the widespread view that cannabis being a “plant” does not carry adverse effects, and review the evidence concerning the effects of cannabis use on mental health and cognition. 2. Understanding cannabis The plant Cannabis sativa contains more than 100 different psychoactive ingredients,33,53,74 but the most widely studied are THC (Δ-9-tetrahydrocannabinol) and CBD (cannabidiol),36,74,84 synthesised from the same precursor, cannabigerol. Therefore, types of cannabis with high concentrations of THC produce low CBD and vice versa.23 THC is a partial agonist at both the cannabinoid receptors (CB) CB2 R and CB1 R, the latter highly abundant in the brain.64, 83, 97 THC is responsible for most of the enjoyable and adverse effects that commonly arise after acute and regular cannabis use.8,24,116 Conversely, CBD is a negative allosteric modulator at the CB1R,76 whose effects are distinct and, in many cases, opposite of those observed with THC. CBD does not induce euphoria but may exert anxiolytic, antiepileptic, anti-inflammatory, and analgesic properties Figure 1.9,10,22,91,99,100,108Figure 1.: This diagram graphically illustrated first, the differential and in fact opposite psychiatric and cognitive effects of THC and of CBD, and second, how both compounds derive from the same precursor. Therefore if, for instance, a Cannabis sativa plant is genetically driven to the production of high quantity of THC, it will only be capable to synthesise small quantities of CBD.103. Cannabis intoxication and dependence 3.1. Acute adverse effects Cannabis use can lead to intoxication, defined as a series of “clinically significant problematic behavioural or psychological changes (eg, impaired motor coordination, euphoria, anxiety, sensation of slowed time, impaired judgment, and social withdrawal) that develop during, or shortly after, cannabis use.”2 The experience of feeling “high” after cannabis use is variable and subjective,48 depending on the dose, the environment, and previous experience and expectations of the drug user.101 The most common acute adverse effects are panic attacks and other forms of anxiety, mostly reported by naive users.50,51 Because cannabis impairs psychomotor skills, reaction time, and motor coordination, its use leads to increased risk of motor vehicle accidents.6,98 Current cannabis users have higher rates of hospitalization for injury from all causes than former cannabis users or nonusers.41 3.2. Cannabis use disorders DSM-5 CUDs is now a single diagnostic entity including abuse and dependence3; it is prevalent (2.54% 12-month prevalence among U.S. adults), associated with comorbidity and disability, and largely untreated.56 Moreover, CUD often presents comorbidly with psychotic disorders.59 Preclinical studies support the evidence that exposure to THC leads to dependence.1,16,19 Cannabis can induce tolerance in humans60,65 and dependence.16 Because cannabis is eliminated slowly from the body, withdrawal symptoms are generally mild. Nevertheless, discontinuation of long-term frequent cannabis use can induce anger, decreased appetite, irritability, nervousness, restlessness, and sleep difficulties,13,79 suggesting that the alleviation of abstinence symptoms contributes to the maintenance of daily cannabis use.52 Recent evidence, from the Netherlands, has shown an association between changes over time in average THC content in the type of cannabis available and rates of admission to specialist cannabis treatment units.37 4. Cannabis and psychosis 4.1. Epidemiological evidence Cross-sectional and prospective studies demonstrate a causal link between cannabis use and psychotic disorder, with greater risk for cannabis users, compared to nonusers.73,85,88,89 The most recent meta-analysis reported a pooled odds
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CU and in particular heavy use (Marconi et al., 2016) has been consistently associated with increased risk for PD, but to a lesser degree for other psychiatric conditions (Sideli, Trotta, Spinazzola, La Cascia, & Di Forti, 2020b).”
From Can epigenetics shine a light on the biological pathways underlying major mental disorders? (2022) · cites this paper as Sideli, Trotta, Spinazzola, La Cascia, & Di Forti, 2020b
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Adverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Adverse health effects of non-medical cannabis use
Hall, W., & Degenhardt, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61037-0 · Cited by 1,134
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Cannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., Ware, M., Marmorstein, N., Cipriani, A., Dendukuri, N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4500 · Cited by 914 · cited 4×
“84) both in general population and clinical samples.(44) Evidence for a weaker association between cannabis use and”
BackgroundInfluentialMeta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw003 · Cited by 899
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30048-3 · Cited by 875
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Soliman, N., Haroutounian, S., Hohmann, A. G., Krane, E. J., Liao, J., Macleod, M. R., Segelcke, D., Sena, C., Thomas, J., Vollert, J., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000002269 · Cited by 153
Can epigenetics shine a light on the biological pathways underlying major mental disorders?
Alameda, L., Trotta, G., Quigley, H., Rodriguez, V., Gadelrab, R., Dwir, D., Dempster, E., Wong, C. C. Y., & Forti, M. D. (2022) · Psychological Medicine · doi:10.1017/s0033291721005559 · Cited by 60
Self-citationTHC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Pintori, N., Caria, F., Luca, M. A. D., & Miliano, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065251 · Cited by 50
Medicinal cannabis in Thailand: 1-year experience after legalization
Zinboonyahgoon, N., Srisuma, S., Limsawart, W., Rice, A. S. C., & Suthisisang, C. C. (2020) · Pain · doi:10.1097/j.pain.0000000000001936 · Cited by 48
Pain management in people with severe mental illness: an agenda for progress
Onwumere, J., Stubbs, B., Stirling, M., Shiers, D., Gaughran, F., Rice, A. S. C., C de C Williams, A., & Scott, W. (2022) · Pain · doi:10.1097/j.pain.0000000000002633 · Cited by 35
Metadata
- Authors
- Sideli, L., Trotta, G., Spinazzola, E., La Cascia, C., & Di Forti, M.
- Affiliations
- King's College London (GB)
- Department of Biomedicine, Neuroscience and Advanced Diagnostic, Palermo University, Palermo, Italy
- Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
- Venue
- Pain
- Published
- 2020-06-17
- Volume
- 162
- Issue
- 1
- Pages
- S97-S104
- ISSN
- 0304-3959 (ISSN-L)
- 1872-6623
- PMC
- PMC8216111
- OpenAlex
- W3049507884
- Cited by
- 36
- References
- 112
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 21 · 2022: 7 · 2021: 2 · 2020: 1
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Pain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/T007818/1)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- cannabis use, adverse effects, THC, cannabidiol, cannabis use disorder, mental health, cognitive impairment, cannabinoid receptors, cannabis legalization, adolescent cannabis use, chronic pain, medical cannabis, neurotoxicity, depression, anxiety, attention, cannabis harm reduction, harm reduction
- MeSH terms
- Brain, Cannabis, Marijuana Abuse, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review